Tandem mass spectrometry was adopted for newborn screening by North Carolina in April 1999. Since then, three infants with short-chain acyl-CoA dehydrogenase (SCAD) and one with isobutyryl-CoA dehydrogenase deficiency were detected on the basis of elevated butyrylcarnitine/isobutyrylcarnitine (C 4 -carnitine) concentrations in newborn blood spots analyzed by tandem mass spectrometry. For three SCAD-deficient infants, biochemical evaluation included a plasma acylcarnitine profile with markedly elevated C 4 -carnitine, urine organic acid analysis with markedly elevated ethylmalonic and 2-methylsuccinic acids, and markedly elevated [U- 13 C]butyrylcarnitine concentrations in medium from fibroblasts incubated with [U- 13 C]palmitic acid and excess L-carnitine, consistent with classic SCAD deficiency. Two of three infants diagnosed with classic SCAD deficiency remained asymptomatic; however, the third infant presented with seizures and a cerebral infarct at 10 wk of age. All three infants had putatively inactivating mutations in both alleles of the SCAD gene. The highly elevated plasma C 4 -carnitine levels in the three infants detected by newborn screening tandem mass spectrometry differentiated them from infants and children who were homozygous or compound heterozygous for one of two SCAD gene susceptibility variations; for the latter group the C 4 -carnitine levels were normal. Isobutyryl-CoA dehydrogenase deficiency in a fourth infant was confirmed after isolated elevation of C 4 Newborn screening programs have been expanded with MS/MS to detect up to 20 additional disorders of metabolism compared with previous methods for newborn screening. Disorders of mitochondrial ␤-oxidation of fatty acids (especially MCAD deficiency), organic acidemias, and disorders of the urea cycle have been identified before the onset of symptoms by newborn screening MS/MS, providing early, beneficial treatment and justifying this approach to newborn screening. However, the evaluation and treatment of some rare disorders of metabolism, including SCAD deficiency, after detection by MS/MS has not been well described.
SCAD deficiency is putatively a very rare disorder, and only 19 cases of this disorder have been described (1) (2) (3) . Among these cases, two distinct classifications have emerged, either classic SCAD deficiency or variant SCAD. The first group consists of patients with marked ethylmalonic aciduria and methylsuccinic aciduria, markedly elevated C 4 -carnitine in the acylcarnitine profile, decreased SCAD activity in fibroblasts, and pathogenic mutations in both alleles of the SCAD gene (when reported). Less than half of the 19 reported cases fit these criteria, and could be considered classic SCAD deficiency such as the first of two cases reported by Amendt et al. (4) . The second, larger group may have intermittent ethylmalonic aciduria, variably decreased SCAD activity, and an SCAD gene susceptibility variation (625 G3 A/G3 A or 511 C3 T/C3 T) in both alleles, sometimes accompanied by a heterozygous inactivating mutation in one SCAD allele (2, 5, 6) . Biochemical abnormalities may be less pronounced in this second group, and clinical abnormalities show marked heterogeneity (1) (2) (3) (4) 7) . Difficulties with the diagnosis of SCAD deficiency may partially explain the paucity of case reports, especially given that fibroblast analysis may not correspond with muscle SCAD activity (J. Vockley, Mayo Clinic, unpublished data). The overlap of these two presentations for SCAD deficiency has created confusion regarding the diagnosis and outcome of SCAD deficiency.
The presence of elevated C 4 -carnitines in the acylcarnitine profile can signal either SCAD deficiency or IBCD deficiency in the asymptomatic newborn. The cutoffs used for C 4 -acylcarnitine by the newborn screening laboratory might play a role in the ascertainment of patients with variant forms of these disorders.
METHODS

MS/MS newborn screening.
Samples were collected by the Guthrie method on cotton-fiber filter-paper circles and were received and processed by the North Carolina State Laboratory. A one-eighth-inch-diameter disc punched from a single dried blood spot was used for MS/MS processing. Samples were extracted and processed according to established methods (8, 9) .
Normal newborn screening results were reported to the infant's physician of record at the completion of testing. Abnormal screening results were reported immediately in writing to the physician of record, and further evaluation and follow-up testing were recommended. If the specimens requested for testing were not received by the state laboratory or contact was not made by the physician within 14 d of notification, the infant's family was notified directly and the recommended testing instructions were relayed. Medical geneticists with expertise in the diagnosis and management of inborn errors of metabolism were available for consultation throughout the screening process.
Biochemical testing and SCAD gene analysis. Urine organic acids were analyzed by capillary gas chromatographymass spectrometry as ethoxime-trimethylsilyl derivatives using a modification of a standard procedure (10).
13 C 3 -EMA (synthesized and characterized in the Duke Mass Spectrometry Facility, data not shown) was added to urine as an internal standard before extraction (approximately 25 mmol/mol creatinine). Full-scan gas chromatography-mass spectrometry data were acquired over the mass range of 50 -600 at a rate of 0.5 s/scan. EMA was quantified by generating ion current chromatograms for m/z 261 (endogenous EMA) and 264 (labeled EMA) from the full-scan data, and comparing the ratio of theses signals to a standard curve (signal ratio versus concentration of added EMA). Plasma acylcarnitines were analyzed either by liquid secondary-ion MS/MS (11-13) with modifications (14) or by electrospray-MS/MS (8) .
SCAD activity in muscle biopsy was determined with butyryl-CoA and octanoyl-CoA as substrates, both before and after inactivation with specific antiserum to MCAD (4, 15) .
SCAD coding and promoter sequence analysis were performed as described (2) . Genomic DNA was prepared from cultured patient fibroblasts by standard methods.
In vitro probe analysis of cultured patient fibroblasts. For in vitro probe analysis confluent skin fibroblasts were incubated with 200 M [U- 13 C]palmitate (generous gift of Cambridge Isotopes Laboratories, Inc., Andove, MA, U.S.A.) and 400 M L-carnitine in serum-free minimal essential medium containing 0.3% (wt/vol) fatty acid-free BSA for the analysis of SCAD deficiency (16) . Similarly, skin fibroblasts were incubated with 800 M [U- Ϫ3 mBar were used. Concentrations were calculated by peak intensity ratios to the internal standards.
Patients. Newborn screening MS/MS and biochemical testing suggested SCAD deficiency for patients A-C (Table 1) , on the basis of markedly elevated C 4 -carnitine in the blood spot and plasma, and markedly elevated EMA and methylsuccinic acid in urine organic acids. Patient D also had markedly elevated C 4 -carnitine in the blood spot and plasma acylcarnitine profiles; however, urine organic acids showed an elevation of isobutyrylglycine rather than EMA and methylsuccinic acids (Table 1) .
Statisical analysis. In the analysis of the samples we used generalized estimating equations and assumed an exchangeable correlation coefficient with a Gaussian relationship. We used generalized estimating equations because there were multiple observations for each subject. We repeated our analysis using only the first observation for each subject using a Wilcoxon rank sum test (data not shown), and the results did not differ substantively.
Reported p values are two-tailed, and the analysis was conducted using STATA 6.0 (College Station, TX, U.S.A.).
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RESULTS
Elevated C 4 -carnitine on newborn screening in SCAD deficiency and in IBCD deficiency. Four infants were evaluated for elevated blood spot C 4 -carnitine on newborn screening by obtaining a plasma acylcarnitine profile and urine organic acid analysis (Table 1) . On follow-up, three of these infants had markedly elevated (at least 3 ϫ the upper limit of normal) EMA and methylsuccinic acid in urine and markedly elevated butyrylcarnitine in plasma consistent with SCAD deficiency (patients A-C). Patient A presented with seizures at 10 wk of age, and a muscle biopsy was performed to measure the muscle SCAD activity, which was deficient (5.1 mU/mg with octanoyl-CoA, and unmeasurable with butyryl-CoA). These results indicated SCAD deficiency in patient A, and probable SCAD deficiency in patients B and C.
As further analysis of SCAD in the above-mentioned patients, sequencing of the SCAD gene was performed (Table 2) . Patients A and B were homozygous for a previously described inactivating mutation, 529T3 C, which substitutes arginine for tryptophan at position 153 (5). In spite of this coincidence, these patients are believed to be unrelated on the basis of pedigree information and differences in ethnic background. Patient C was heterozygous for a nonsense mutation at position 137, and for a missense mutation that substitutes phenylalanine for serine at position 111. Patients A and B had the normal sequence for the SCAD gene susceptibility variation at nucleotides 511 and 625, and patient C was heterozygous for the sequence variation at nucleotide 511 (Table 2) . In patient C, the 511 C3 T SCAD gene susceptibility variation was linked with the missense mutation at amino acid position 111.
Patient D was initially evaluated for suspected SCAD deficiency on the basis of elevated blood spot C 4 -carnitine on newborn screening (Table 1) , which suggested increased butyrylcarnitine. However, urine organic acids showed elevated isobutyrylglycine with no elevation of EMA, and this result was consistent with elevated isobutyrylcarnitine and IBCD deficiency. Further confirmation was pursued by in vitro probe analysis of cultured fibroblasts (below).
Differentiation of classic SCAD deficiency from patients with SCAD gene variants. It is possible to ascertain at least some SCAD variants by newborn screening if the cutoff for C 4 -carnitine is more aggressive than that used in North Carolina (Dr. Steven Levine, Newborn Screening Laboratory, Berkeley, CA, U.S.A., personal communication). Accordingly, we compared the results of repeated plasma C 4 -carnitine and urinary EMA determinations of the three infants with biochemical profiles typical of classic SCAD deficiency and five patients with variant SCAD. Patients with variant SCAD were homozygotes or compound heterozygotes for SCAD gene susceptibility variations 625 G3 A and 511 C3 T. The plasma C 4 -carnitine was significantly elevated (p Ͻ 0.001) by greater than 14-fold in the three infants with classic SCAD deficiency (mean Ϯ SD, 4.63 Ϯ 1.60 M, n ϭ 17; mean age Ϯ SD, 332 Ϯ 274 d) compared with the variant SCAD patients, for whom plasma C 4 -carnitine concentrations were within the normal range (Ͻ0.46 M). C 4 -carnitine concentrations remained consistently elevated in plasma for the patients with classic SCAD deficiency. The patients with variant SCAD, none of whom were ascertained by newborn screening, were evaluated for various clinical presentations, and initially had mildly elevated EMA and methylsuccinic acid (Ͻ2 ϫ the upper limit of normal) in urine that did not persist on repeated testing. EMA (controls Ͻ 16 mmol/mol creatinine) was always significantly elevated (p ϭ 0.02) in classic SCAD-deficient patients (mean Ϯ SD, 160 Ϯ 130 mmol/mol creatinine, n ϭ 7; mean age Ϯ SD, 603 Ϯ 188 d). In summary, patients with classic SCAD deficiency were readily distinguished from those with variant SCAD by the plasma acylcarnitine profile and urine organic acid analysis.
In vitro probe analysis of cultured fibroblasts in SCAD deficiency and in IBCD deficiency. In vitro probe analysis of cultured fibroblasts from the three infants with putative SCAD deficiency demonstrated that [U-
13 C]C 4 -carnitine (absolute concentrations and concentrations normalized to [U- 13 C]C 16 -carnitine) was markedly elevated in the medium compared (Table 4 ), indicating that the activity of 2-methylbutyryl-CoA dehydrogenase was normal.
DISCUSSION
A common dilemma in the evaluation of patients with symptomatic hypoglycemia or those with neurologic symptoms is the interpretation of relatively mild elevations in metabolites in organic acid and acylcarnitine profiles. This difficulty is especially challenging when diagnostic tests require invasive procedures to obtain the relevant tissue for enzyme testing, such as a muscle biopsy in the case of SCAD deficiency. The situation is considerably more complex in the presentation of a normal infant detected by MS/MS newborn screening, such as the elevations of a single metabolite, C 4 -carnitine (representing either butyrylcarnitine or isobutyrylcarnitine), found in the patients presented above. Nevertheless, a complete evaluation including analysis of cultured fibroblasts clarified the underlying enzyme deficiency for these three patients, and SCAD deficiency was confirmed by molecular analysis. These patients are characteristic of the classic form of SCAD deficiency, characterized by markedly and persistently elevated C 4 -carnitine in plasma and EMA and 2-methylsuccinic acids in urine. The diagnosis of three patients with classic SCAD deficiency between the initiation of expanded newborn screening with MS/MS by North Carolina on April 20, 1999, and December 21, 2001 , when 320,503 infants were screened (17), suggested an incidence of approximately 1 in 100,000 newborns for SCAD deficiency. Given the detection of only one infant with IBCD deficiency during that interval, this disorder may be quite rare among the population of North Carolina.
We speculate that SCAD deficiency is less rare than previously expected, because the three patients reported here were unrelated and of different ethnicity. The increased detection of rare disorders in newborns using MS/MS can be explained by several possibilities, including random fluctuation in the population or previous underascertainment. Other groups have reported detection of SCAD deficiency by MS/MS newborn screening, although SCAD activity and genetic analysis for those patients were not reported (18, 19) . However, in Massachusetts four of five infants reportedly had increased urinary ethylmalonate and methylsuccinate or increased plasma C 4 -carnitine, which suggested classic SCAD deficiency in approximately 1 in 40,000 births (19) . Given the low number of cases in each report and accompanying wide confidence intervals, these two estimates of the incidence of SCAD deficiency are essentially equivalent.
Treatment of SCAD deficiency and IBCD deficiency in the asymptomatic infants presented here is justified on several considerations. Rational treatment, including avoidance of fasting, supplementation of carbohydrates to limit fatty acid or amino acid catabolism when stressed, and supplementation of riboflavin, a cofactor for dehydrogenases (1, 20) , is available for both disorders. In addition, moderate protein restriction could be beneficial in isobutyryl CoA dehydrogenase deficiency by virtue of reducing the valine intake. A significant risk for disease, including hypoglycemia and CNS damage in SCAD deficiency (1, 2, 7) and low carnitine with cardiomyopathy in IBCD deficiency (21) , has been reported in both disorders. Indeed, patient A presented with seizures as reported in other patients with classic SCAD deficiency. It should be noted, however, that the infarct in patient A might not have been a direct cause of SCAD deficiency.
Each of the SCAD patients reported here has two putatively inactivating mutations in the SCAD gene, either missense or nonsense mutations. Patients A and B were homozygous for 529T3 C, which substitutes arginine for tryptophan at position 153 (5) . When the 529T3 C SCAD variant was expressed in COS-7 cells, the variant protein had very low residual SCAD activity (5) . The mutations in patient C consisted of a nonsense mutation at codon 137, most probably causing rapid degradation of the corresponding mRNA by the nonsense-mediated decay mechanism (22) . Alternatively, the protein-if synthesized-will be prematurely terminated with removal of 251 amino acids, including the active center. Likewise, the second mutation in patient C, phenylalanine for serine at position 111, could be predicted to inactivate the SCAD protein because it is a nonconservative amino acid substitution at a position conserved in the mouse and rat SCAD proteins (23) . Patient C also carried the 511C3 T SCAD gene susceptibility variation, previously found to destabilize the SCAD protein (5), and this destabilizing sequence variation was linked with a potentially inactivating mutation, the missense mutation at position 111. Moreover, markedly increased plasma C 4 -carnitine levels dif- 222 ferentiated the infants with classic SCAD deficiency from patients with variant SCAD, either homozygous or compound heterozygous for the common SCAD gene susceptibility variation (625G3 A and 511C3 T). The natural history of patients with SCAD gene susceptibility variation remains uncertain, especially given the variable presentation of patients with these genotypes (2) . Ascertainment of variant SCAD by MS/MS newborn screening will depend on the value of the normal cutoff (upper limit of the normal range) used by the newborn screening laboratory, which varies from state to state. However, the C 4 -carnitine levels in newborn screening may be low enough to preclude detection of those infants with variant SCAD, given the current cutoff value for C 4 -carnitine in Minnesota (24) and in North Carolina. In North Carolina, we have not detected any infant with variant SCAD by newborn screening using a cutoff value of the mean ϩ 4 SDs. The differentiation between two rare disorders of metabolism in this group of infants with elevated C 4 -carnitine in newborn screening MS/MS emphasized the need for thorough follow-up evaluations of infants with abnormal blood spot acylcarnitines. Biochemical evaluation consisting of a plasma acylcarnitine profile and urine organic acids, followed by in vitro acylcarnitine profiling and sequencing of the SCAD gene, allowed confirmation of classic SCAD deficiency in three infants. This stepwise approach to the evaluation of SCAD deficiency could obviate the need for a muscle biopsy to demonstrate this disorder, especially in otherwise healthy infants. Finally, a similar approach was applied to establish isobutyrylglycinuria, and quantitative in vitro acylcarnitine profiling provided evidence for a defect of isobutyryl-CoA dehydrogenase in only the second individual shown to have this disorder (21) . The ability to recognize and quantify the urinary metabolites for these disorders is dependent on the experience and expertise of the laboratory that performs the follow-up tests after an abnormal newborn screen. We therefore recommend that such tests should be entrusted only to laboratories with proven experience and reliability.
